A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 4, 2012, Pages 323-330

  Watanabe, Ryo ^a   Ogawa, Masahito ^b   Suzuki, Jun Ichi ^b   Hirata, Yasunobu ^b   Nagai, Ryozo ^b   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

angiotensin converting enzyme; myocardial ischemia; ventricular remodeling

Indexed keywords

CARBOXYMETHYLCELLULOSE; COLLAGEN; COMPLEMENTARY DNA; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; IMIDAPRIL; RAMIPRIL; RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ASSAY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; MALE; NEWBORN; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; IMIDAZOLIDINES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; RAMIPRIL; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 84859882367     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182422c1a     Document Type: Article

References (33)

1. Brower GL, Levick SP, Janicki JS. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol. 2007;292: H3057-H3064. (Pubitemid 47084560)
2. Sakata Y, Yamamoto K, Mano T, et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation. 2004;109:2143-2149. (Pubitemid 38620225)
3. Westermann D, Riad A, Lettau O, et al. Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension. 2008;52:1068-1075.
4. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000; 52:11-34. (Pubitemid 30127593)
5. Yamamoto D, Takai S, Jin D, et al. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol. 2007;43:670-676. (Pubitemid 350166378)
6. Sorbi D, Fadly M, Hicks R, et al. Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. Kidney Int. 1993;44:1266-1272. (Pubitemid 23353308)
7. Maggioni AP, Latini R. Ramipril following acute MI attenuated LV remodeling. Evid Based Cardiovasc Med. 1998;2:13.
8. Dagenais GR, Pogue J, Teo KK, et al. Impact of ramipril on the circadian periodicity of acute myocardial infarction. Am J Cardiol. 2006;98: 758-760. (Pubitemid 44313881)
9. Bosch J, Lonn E, Pogue J, et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the hope study extension. Circulation. 2005;112:1339-1346. (Pubitemid 41266730)
10. Dolezal T. Imidapril in heart failure. J Renin Angiotensin Aldosterone Syst. 2006;7:146-154.
11. Wang J, Liu X, Ren B, et al. Modification of myosin gene expression by imidapril in failing heart due to myocardial infarction. J Mol Cell Cardiol. 2002 847-857. (Pubitemid 35205186)
12. Seeland U, Kouchi I, Zolk O, et al. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol. 2002 151-163. (Pubitemid 35222825)
13. Sandmann S, Yu M, Unger T. Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction-effects of AT (1) and AT(2) receptor antagonists and ace inhibitor. Br J Pharmacol. 2001;132:767-777. (Pubitemid 32165193)
14. Saini HK, Shao Q, Musat S, et al. Imidapril treatment improves the attenuated inotropic and intracellular calcium responses to ATP in heart failure due to myocardial infarction. Br J Pharmacol. 2005;144:202-211. (Pubitemid 40216118)
15. Maejima Y, Adachi S, Morikawa K, et al. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via s-nitrosylation. J Mol Cell Cardiol. 2005;38:163-174. (Pubitemid 40038663)
16. de Resende MM, Kauser K, Mill JG. Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats. Life Sci. 2006;78:3066-3073.
17. Isobe K, Kuba K, Maejima Y, et al. Inhibition of endostatin/collagen XVIII deteriorates left ventricular remodeling and heart failure in rat myocardial infarction model. Circ J. 2010;74:109-119.
18. Re RN. Myocardial hypertrophy, angiotensin, and ace inhibitors. Angiology. 1993;44:875-881. (Pubitemid 23333223)
19. Weber KT, Brilla CG, Campbell SE, et al. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993;88(suppl 1): 107-124. (Pubitemid 23226442)
20. Johnston CI, Fabris B, Yoshida K. The cardiac renin-angiotensin system in heart failure. Am Heart J. 1993;126:756-760. (Pubitemid 23264854)
21. Beckwith C, Munger MA. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction. Ann Pharmacother. 1993;27:755-766. (Pubitemid 23184914)
22. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123:255-278.
23. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res. 2009;81:482-490.
24. Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ace inhibitors. Curr Med Chem. 2009;16:1349-1354.
25. Xu Y, Tang T, Ding Y, et al. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction. Am J Med Sci. 2010;340:121-127.
26. Berthonneche C, Sulpice T, Boucher F, et al. New insights into the pathological role of TNF-alpha in early cardiac dysfunction and subsequent heart failure after infarction in rats. Am J Physiol Heart Circ Physiol. 2004;287:H340-H350. (Pubitemid 38802370)
27. Kohno T, Anzai T, Naito K, et al. Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling. Circ J. 2008;72:1685-1692.
28. Trescher K, Bernecker O, Fellner B, et al. Inflammation and postinfarct remodeling: overexpression of IkappaB prevents ventricular dilation via increasing TIMP levels. Cardiovasc Res. 2006;69:746-754. (Pubitemid 43139737)
29. Onai Y, Suzuki J, Maejima Y, et al. Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol. 2007;292:H530-H538. (Pubitemid 46105217)
30. Vanhoutte D, Schellings M, Pinto Y, et al. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res. 2006;69:604-613. (Pubitemid 43139724)
31. Mukherjee R, Rivers WT, Ruddy JM, et al. Long-term localized highfrequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation. 2010;1: 20-32.
32. Ramani R, Nilles K, Gibson G, et al. Tissue inhibitor of metalloproteinase- 2 gene delivery ameliorates postinfarction cardiac remodeling. Clin Transl Sci. 2011;4:24-31.
33. Jayasankar V, Woo YJ, Bish LT, et al. Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy. Circulation. 2004;110:II180-II186. (Pubitemid 39263720)